Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Jetstar to Charge for Overhead Cabin Bags From February 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
TEL AVIV, Israel, March 09, 2018 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 15 at 8:30am Eastern Time to report fiscal year ended December 31, 2017 financial results.
| Thursday, March 15th @ 8:30am Eastern Time | ||
| Domestic: | 877-222-6394 | |
| International: | 703-925-2702 | |
| Conference ID: | 7392936 | |
| Webcast: | https://edge.media-server.com/m6/p/y3srj89d | |
| Replays, Available through March 29th: | ||
| Domestic: | 855-859-2056 | |
| International: | 404-537-3406 | |
| Conference ID: | 7392936 | |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
MEDIA CONTACT:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
(646) 627-8384
